Linkus® BSS (Syrup) Instructions for Use
Marketing Authorization Holder
Herbion Pakistan, Private Limited (Pakistan)
ATC Code
R05CA10 (Expectorants in combination)
Dosage Form
| Linkus® BSS | Syrup 90 ml: bottle |
Dosage Form, Packaging, and Composition
Syrup brown in color with a characteristic odor; a slight sediment may be present, which disappears upon shaking.
| 10 ml | |
| Dry extract of Adhatoda vasica leaves | 600 mg |
| Dry extract of Glycyrrhiza glabra roots | 75 mg |
| Dry extract of Piper longum fruits and roots | 100 mg |
| Dry extract of Viola odorata flowers | 25 mg |
| Dry extract of Hyssopus officinalis leaves | 50 mg |
| Dry extract of Alpinia galanga roots and rhizomes | 50 mg |
| Dry extract of Cordia latifolia fruits | 100 mg |
| Dry extract of Althaea officinalis flowers | 100 mg |
| Dry extract of Ziziphus jujuba fruits | 100 mg |
| Dry extract of Onosma bracteatum leaves and flowers | 100 mg |
Excipients: sodium saccharin 15 mg, citric acid 20 mg, glycerol 1 g, propylene glycol 1.252 g, sorbitol solution 70% 4 g, methylparaben 10.928 mg, propylparaben 2.168 mg, peppermint oil 2.75 µl, clove oil 1.25 µl, purified water up to 10 ml.
90 ml – brown glass bottles (1) – cardboard boxes.
120 ml – brown glass bottles (1) – cardboard boxes.
150 ml – brown glass bottles (1) – cardboard boxes.
Clinical-Pharmacological Group
Herbal preparation with expectorant effect
Pharmacotherapeutic Group
Herbal remedy
Pharmacological Action
A combined herbal preparation. Reduces the intensity and increases the productivity of cough, has expectorant, mucolytic and anti-inflammatory effects.
Adhatoda vasica has antitussive, bronchodilator, expectorant, and antispasmodic effects.
Glycyrrhiza glabra root contains glycyrrhizin and foaming agents – saponins, which help increase the secretory function of the respiratory tract epithelium, change the surface-active properties of pulmonary surfactant, stimulate the movement of epithelial cilia, thin sputum and facilitate its discharge. It has a suppressive effect on the exudative and proliferative phases of inflammation. It has antiallergic properties.
Piper longum has antibacterial and antiallergic properties. It has antitussive and general tonic effects.
Viola odorata has anti-inflammatory, analgesic, soothing, antimicrobial, and antispasmodic effects.
Hyssopus officinalis contains diosmin, which has antiseptic, anti-inflammatory, analgesic, and antitussive effects.
Alpinia galanga has a bactericidal effect and possesses anti-inflammatory and expectorant properties.
Althaea officinalis has expectorant and anti-inflammatory effects.
Ziziphus jujuba has an expectorant effect, reduces sore throat, and has sedative and antibacterial properties.
Indications
Symptomatic therapy of infectious and inflammatory diseases of the respiratory tract, accompanied by cough with difficult-to-discharge sputum (against the background of ARVI, influenza, tracheitis, bronchitis, tracheobronchitis, pneumonia, smoker’s bronchitis and other inflammatory diseases of the respiratory tract).
ICD codes
| ICD-10 code | Indication |
| J04 | Acute laryngitis and tracheitis |
| J06.9 | Acute upper respiratory infection, unspecified |
| J10 | Influenza due to identified seasonal influenza virus |
| J15 | Bacterial pneumonia, not elsewhere classified |
| J20 | Acute bronchitis |
| J37 | Chronic laryngitis and laryngotracheitis |
| J42 | Unspecified chronic bronchitis |
| R05 | Cough |
| ICD-11 code | Indication |
| 1E30 | Influenza due to identified seasonal influenza virus |
| CA05 | Acute laryngitis or tracheitis |
| CA07.0 | Acute upper respiratory tract infection of unspecified site |
| CA0G | Chronic laryngitis or laryngotracheitis |
| CA20.1Z | Chronic bronchitis, unspecified |
| CA40.0Z | Bacterial pneumonia, unspecified |
| CA42.Z | Acute bronchitis, unspecified |
| MD12 | Cough |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Administer orally. Shake the bottle thoroughly before each use.
For adults and children over 12 years: take 2 teaspoons (10 ml) three times daily.
For children from 6 to 12 years: take 1 teaspoon (5 ml) three times daily.
For children from 2 to 6 years: take 1/2 teaspoon (2.5 ml) three times daily.
For children from 6 months to 2 years: take 1/4 teaspoon (1.25 ml) three times daily.
Contraindicated for children under 6 months of age.
Take the dose after meals. The duration of use depends on the clinical picture; continue for several days after symptom resolution.
Do not exceed the recommended duration of continuous use without medical consultation.
Avoid concomitant use with antitussive medications or drugs that reduce sputum formation.
Adverse Reactions
Rarely allergic reactions.
Contraindications
Increased individual sensitivity to the components of the drug; children under 6 months of age.
Use in Pregnancy and Lactation
Not recommended for use during pregnancy and lactation.
Pediatric Use
Contraindicated in children under 6 months of age.
Special Precautions
Concomitant use with antitussive medicinal products, as well as with drugs that reduce sputum formation, is not recommended.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer